NOVANTA INC (NOVT) Financial Ratio Screen

NASDAQ Technology United States USD 5378M
INSUFFICIENT / NOT IMPLEMENTED*
Automated financial screen · activity assessed separately
NOVANTA INC (NOVT) needs additional financial data before the automated screen can be completed. One or more financial fields are missing; this is not a negative screening result.

Track NOVT screening changes

Get an email when this stock's published screening status or underlying ratios change.

MSCI new-inclusion financial-ratio snapshot

NOVT financial screening at a glance

INSUFFICIENT / NOT IMPLEMENTED*Financial ratios shown separately from business review — not a fatwa
Debt ratio
16.7%
Pass vs 30%
Cash ratio
21.1%
Pass vs 30%
Receivables + cash
31.8%
Fail vs 30%
Impermissible income
N/A
Not available vs 5%

Calculation date: 2026-08-31. Financial period used: December 2025. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.

Independent method comparison

What the available screens say

How MSCI, FTSE and S&P-style screens differ
Request this stock review
MSCI-styleMore financial data neededNo negative conclusion follows from missing data
FTSE/Yasaar-styleMore financial data neededNo negative conclusion follows from missing data
S&P-style provisionalNot yet availableRequired denominator or financial data is incomplete
Business activityAssessment pendingFinancial results do not determine business permissibility
Complete screening result: not yet completeA complete result requires both supported financial criteria and adequate activity evidence. This site does not issue a fatwa or official index decision.
Financial periodDecember 2025Calculation date2026-08-31S&P-style historynot availableLast activity reviewnot yet reviewed

The request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.

Business activity evidence

Activity assessment in progress

The supplied classification (Scientific & Technical Instruments) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.

Revenue segments: Not yet checked against an SEC annual filing.

Profile description reviewed: Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures, such as ophthalmology applications. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; imaging, identification and RFID solutions; advanced motion control solutions; and light engines, and integrated operating room technologies. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is based in Bedford, Massachusetts.

Sources to verify: Secondary company profile and classification · Issuer website · SEC issuer filings

A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.

Published-ratio reproductions (not certifications)

The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style leverage reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
MSCI 16.7%
/ 30%
21.1%
/ 30%
31.8%
/ 30%
N/A INSUFFICIENT / NOT IMPLEMENTED*
FTSE 16.7%
/ 33%
21.1%
/ 33%
31.8%
/ 50%
N/A INSUFFICIENT / NOT IMPLEMENTED*

Financial Highlights

P/E Ratio
90.0
Forward: 32.6
EPS
$1.58
P/B Ratio
3.3
EV/EBITDA
27.8
EV: $5.0B
Revenue
$981M
Growth: 10.3%
Beta
1.7
High volatility
Current Ratio
4.6

Profitability

Gross Margin 44.5%
Operating Margin 11.5%
Net Margin 6.0%
Return on Equity (ROE) 5.1%
Return on Assets (ROA) 4.1%

Cash Flow & Balance Sheet

Operating Cash Flow$64M
Free Cash Flow$48M
Total Debt$302M
Debt-to-Equity17.7
Current Ratio4.6
Total Assets$1.8B

Price & Trading

Last Close$144.65
50-Day MA$152.30
200-Day MA$136.42
Avg Volume499K
Beta1.7
52-Week Range
$98.27
$176.38

Financial data provenance and verification

The displayed fields were imported from yfinance on 2026-08-29 for the financial period December 2025. This is a secondary data feed and can differ from amended or newly filed statements.

Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.

About NOVANTA INC (NOVT)

CEO
Mr. Matthijs Glastra
Employees
3,000
Sector
Technology
Industry
Scientific & Technical Instruments
Country
United States
Exchange
NASDAQ
Market Cap (listing currency)
USD 5378M
Currency
USD

Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures, such as ophthalmology applications. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; imaging, identification and RFID solutions; advanced motion control solutions; and light engines, and integrated operating room technologies. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is based in Bedford, Massachusetts.

Popular halal stock checks

Explore other frequently viewed automated stock screens and compare the available financial ratios.

Frequently Asked Questions

Is NOVANTA INC (NOVT) halal to invest in?

The current automated result is More financial data is needed. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.

What is NOVANTA INC's debt ratio?

NOVANTA INC's debt ratio is 16.7% in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.

What are NOVANTA INC's key financial metrics?

NOVANTA INC has a market capitalization of USD 5378M in its listing currency, trailing P/E ratio of 90.0, and revenue of $981M. The company maintains a gross margin of 44.5% and a net margin of 6.0%. Return on equity stands at 5.1%.

How often is the screening data updated?

Calculation date: 2026-08-31. Financial period: December 2025. These dates are shown separately because regenerating this page does not refresh the underlying data.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.